3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
4
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Oxaliplatin
30
Gemcitabine
28
Fluorouracil
27
Capecitabine
22
Leucovorin
19
pembrolizumab
15
130-nm albumin-bound paclitaxel
13
Irinotecan
12
Cisplatin
11
Bevacizumab
11
Albumin-Bound Paclitaxel
11
Paclitaxel
10
Ramucirumab
8
Radiotherapy
8
Docetaxel
8
Nivolumab
7
trastuzumab deruxtecan
6
Cyclophosphamide
6
Taxes
5
Drug Therapy
5
durvalumab
4
Trastuzumab
4
Metformin
4
zolbetuximab
3
spartalizumab
3
folfirinox
3
cemiplimab
3
XELOX
3
Surgical Procedures, Operative
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
rucaparib
×
Gastrointestinal
×
Clear all
NCT03995017
2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2
Unknown
34 enrolled